Treatment of Synchronous Mantle Cell Lymphoma and Small Lymphocytic Lymphoma with Bendamustine and Rituximab

Publisher： Karger

E-ISSN： 1421-9662|126|1|40-43

ISSN： 0001-5792

Source： Acta Haematologica, Vol.126, Iss.1, 2011-03, pp. : 40-43

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bendamustine plus rituximab for indolent B‐cell lymphoma of renal significance

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 356-362

John Wiley & Sons Inc

Access to resources Recommend Favorite

Synchronous Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia and Melanoma in a Single Lymph Node

By  

Acta Haematologica, Vol. 123, Iss. 3, 2010-03 ,pp. : 194-196

Karger

Access to resources Recommend Favorite

Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 170, Iss. 5, 2015-09 ,pp. : 657-668

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Lymphoma

By  

Oncology, Vol. 65, Iss. 4, 2004-01 ,pp. : 306-310

Karger

Access to resources Recommend Favorite

Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma

By  

Case Reports in Oncology, Vol. 10, Iss. 1, 2017-01 ,pp. : 127-129

Karger

Access to resources Recommend Favorite